Latest oncology insights for medical professionals and patients | curating cancer news, trials, & advances in cancer care |Own Views| Not medical advice
Joined November 2024
- Tweets 1,535
- Following 721
- Followers 877
- Likes 1,527
175 Photos and videos
🚨 New in @NEJM: RRMM Data: #MonumenTAL-3
Talquetamab (GPRC5D×CD3) dara (± pom) vs DPd in relapsed/refractory MM
24-mo PFS:
🔑 Both Talq-Dara-Pom and Talq-Dara beat ✅ DPd in PFS and OS
🔗 nejm.org/doi/full/10.1056/NE…
#mmsm #MedTwitter #OncTwitter @RahulBanerjeeMD @HadidiSamer
2
5
293
OncUpdates retweeted
#mmsm #EHA26 MonumenTAL-3
Published @NEJM
➡️ nejm.org/doi/full/10.1056/NE…
✅RCT, phase 3: Tal-DP vs Tal-D vs DPd
✅ Treatment was until progression or intolerance (not time-limited)
✅ Early relapse ≥1 prior line including lenalidomide PI ( no anti-CD38 refractory)
✅allowed for T-cell redirecting >3 months
🧵
1
10
20
1,313
OncUpdates retweeted
Just out: presented at #EHA26 and published @NEJM
Randomized trial of 2 talquetamab combinations vs DPd in relapsed myeloma. The Monumental-3 trial.
Both Talq-Dara-Pom and Talq-Dara beat DPd in PFS and OS.
Choice of a Talq combination vs Tec or Tec-Dara in relapsed myeloma will be driven by patient and disease factors and requires significant expertise. Congrats @RobertoMinaMD @PlasmaCellPete @mbeksac56 @paurotero @mvmateos @thanosdimop @RahulBanerjeeMD et al.
nejm.org/doi/full/10.1056/NE…
2
31
92
8,680
🚨 #HERIZON-GEA-01 Updates & Sequencing HER2-Directed Therapies #GastricCancer
🎙️ Dr.KU & @SteveMaronMD 🗣️:
✅ Zani tislelizumab chemo improves PFS/OS
❗️Retest HER2 at progression #gism #OncTwitter #MedTwitter #ASCO26 @MSKCancerCenter
🔗 Full 🎥👇
oncupdates.com/video-podcast…
1
2
6
198
OncUpdates retweeted
Jun 12
Belzutifan Pembro now @US_FDA ✅ based off LITESPARK-022: PhIII (vs. Pembro) in adj RCC:
- 2.5yrs DFS: 75.8% vs. 68.6% (HR: 0.72)
- mOS NR
- 2.5yrs OS: 95.6% vs. 93.8% (HR: 0.78)
- AEs: 42.2% vs. 17.9% w/ Gr ≥ 3
#MedTwitter #gusm #KidneyCancer @OncoAlert
2
33
58
4,355
OncUpdates retweeted
Jun 10
🚨 #RASolute-302 & Its Impact on #GI #Oncology @Charbel_matar1 @Deebacca
✅ Median OS (13.2 vs 6.7 months)
✅ Benefits across RAS mutant & wild-type!
👏Standing ovation at #ASCO26! Watch full 🗣️👇
#PancreaticCancer #gism #OncTwitter #MedTwitter #pcsm
oncupdates.com/video-podcast…
6
8
398
OncUpdates retweeted
Jun 11
🚨 #MATTERHORN Update & HCC Challenges in #GIOnc #ASCO26
🎙️ @realbowtiedoc & @rachnatshroff Discuss 🗣️:
✅ Follow-up analysis data presented @ASCO
✅ Immunotherapy based regimens for #HCC
#OncTwitter #gism #MedTwitter #MedX @UAZCancer
🔗 Full video👇
oncupdates.com/video-podcast…
8
18
1,765
OncUpdates retweeted
Jun 12
What were you feeling when you first saw the data? 🤯🤯
#OncTwitter #MedTwitter #MedX #RASolute302 @OncUpdates @OncoAlert
Jun 11
RASOLUTE-302 (GI Conference Highlights) from #ASCO26 w/ #BrianWolpin from @DanaFarber
✅ Other GI studies covered in our next episode w/ @NVijayvergiaMD
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ oncbrothers.com/rasolute-302…
#OncTwitter #MedTwitter #gism @OncUpdates
2
9
16
2,153
Jun 12
🚨 Transformational Data: #HERIZON-GEA-01 & #RASolute-302
🎙️ @GIcancerDoc & @ShrutiPatelMD:
✅ HERIZON-GEA-01: poised for approval in HER2 mGEA
✅ RASolute-302: Daraxonrasib DOUBLES OS in met #PancreaticCancer
#gism #OncTwitter #MedTwitter
Full 🗣️👇
oncupdates.com/video-podcast…
5
8
310
OncUpdates retweeted
Did a fun 5-minute interview with my mentor @apolo_andrea about EV/pembro in bladder cancer oncupdates.com/video-podcast… @OncBrothers @OncUpdates
5
11
1,033
OncUpdates retweeted
A joy to interview an outstanding doc in #GIonc Dr @rachnatshroff about the best updates in the #UGI world for #ASCO26. Thanks for the opportunity @OncUpdates
@RyanNipp
@UgrewalMD
@NiuSanford
@ShaalanBeg
@ShrutiPatelMD
@ARosen380
@TimothyJBrownMD
@OncBrothers
@GIMedOnc
@Erman_Akkus
Jun 11
🚨 #MATTERHORN Update & HCC Challenges in #GIOnc #ASCO26
🎙️ @realbowtiedoc & @rachnatshroff Discuss 🗣️:
✅ Follow-up analysis data presented @ASCO
✅ Immunotherapy based regimens for #HCC
#OncTwitter #gism #MedTwitter #MedX @UAZCancer
🔗 Full video👇
oncupdates.com/video-podcast…
5
16
995
OncUpdates retweeted
Jun 8
⭐️Optimizing CAR-T for #MultipleMyeloma in #CommunityOncology
🎙️@OncBrothers w/@DimaDanai @fredhutch
👉Cilta-cel now 2L post-CARTITUDE-4
👉Early referral tertiary center partnerships
👉Optimize bridging & manage long-term toxicities
#mmsm #OncTwitter
oncupdates.com/video-podcast…
3
4
298
OncUpdates retweeted
Jun 8
⭐️Building off #ASCO26, exciting news in #pancreaticcancer 👇!
#OncTwitter #RASRevolution #MedTwitter #MedX #gism #Oncology #GIOnc @DanaFarber @OncBrothers @TheGutOncLab #cancerresearch #clinicaltrials
🔥Exciting early signals for vopimetostat (TNG462) daraxonrasib in MTAP-deleted #pancreatic ductal adenocarcinoma
👉In this ongoing Ph1/2 combo (2/3L setting):
‼️ORR 92%
✅DCR 100%
✅90% 6-month PFS rate in #PDAC (median PFS NR)
#OncTwitter #MedTwitter #gism #Oncology #MedX
6
7
833
OncUpdates retweeted
Jun 11
RASOLUTE-302 (GI Conference Highlights) from #ASCO26 w/ #BrianWolpin from @DanaFarber
✅ Other GI studies covered in our next episode w/ @NVijayvergiaMD
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ oncbrothers.com/rasolute-302…
#OncTwitter #MedTwitter #gism @OncUpdates
11
22
5,518
OncUpdates retweeted
Jun 9
Results of the T-DXd/durva arm of #BEGONIA for 1L mTNBC are now out in @NatureCancer. High efficacy, with ORR 62% and mPFS 12.6 months. Strikingly, deep responses observed even in HER2-0 (null) dz, reminding that IHC is a poorly predictive ADC biomarker. nature.com/articles/s43018-0…
4
38
134
11,132
OncUpdates retweeted
Here are the 4 studies we touched on during our Head & Neck Ca and Sarcoma #ASCO26 highlights with @AriRosenbergMD @TwoOncDocs
✅ Abs 6004
✅ OrigAMI-4
✅ SARC041
✅ PEAK
#OncTwitter #MedTwitter #MedX @OncUpdates @OncoAlert
Head & Neck Cancer and Sarcoma Conference Highlights from #ASCO26 w/ @AriRosenbergMD & @TwoOncDocs (Sam)
✅ Abstract 6004
✅ #OrigAMI4
✅ #SARC041
✅ #PEAK
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ oncbrothers.com/headandneck-…
#OncTwitter #MedTwitter #hncsm @OncUpdates
22
43
6,593
Jun 9
🚨#ASCO26 CAR-T Update: #MultipleMyeloma
🎙️@OncBrothers sit down with @HadidiSamer to break down 🔑 cilta-cel data from #CARTITUDE-4
✅ Safe & effective in high-risk cytogenetics
✅ Manageable toxicity profile
#mmsm #OncTwitter #MedX @utswcancer
🗣️👇
oncupdates.com/video-podcast…
3
7
436
OncUpdates retweeted
Jun 8
I’m quite ecstatic with this development. Do we dare to dream ? I know it is a small number of patients but the science is strong here and pancreatic cancer needs to keep the momentum of #ASCO26!!
@DanaFarber_Hale @ASCO #pancreaticcancer
Last year, we reported that KRAS PRMT5 is synergistic in MTAP-null PDAC (doi.org/10.1158/0008-5472.CA…). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.
RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD
2
11
70
10,664